Save
Email
Print
ShareApr. 5, 2010 — Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.
One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally identified for its role in the development of breast cancer. SCR3 has also been characterized as a key factor in the development of prostate cancer, but, until now, the exact relationship between androgen receptor and SCR3 has been unclear.
Understanding the relationship between these two proteins, and targeting this interaction, could lead to new, more effective treatments for prostate cancer, the most common form of cancer in men, with more than 192,000 new cases and more than 27,000 deaths reported in the United States in 2009, according to the National Cancer Institute.
"Anti-androgen therapies become less effective over time," said VARI Distinguished Scientific Investigator H. Eric Xu, Ph.D., whose laboratory published the findings recently in the Journal of Biological Chemistry. "To develop the next generation of prostate cancer treatments, we need to find ways to disrupt the interaction between androgen receptor and the molecules it depends on to work, such as SRC3."
Androgen receptor activity is required for the initiation and development of prostate cancer. When activated by hormones, androgen receptor binds to DNA in the cell nucleus and regulates gene expression with the help of molecules called coactivators, including SRC3. As a result, genes create more or less of specific proteins in the cell, which can affect cell behavior. Although androgen receptor needs coactivators such as SRC3 to have an effect, little has been known about precisely how androgen receptor interacts with its coactivators.
VARI researchers used peptide profiling and other techniques of molecular biology to discover that SRC3 is a preferred coactivator for androgen receptor. They went on to determine the crystal structures that reveal how androgen receptor and SRC3 interact at the molecular level. This detailed information could be used to develop new, more effective treatments that disrupt interaction between the two proteins.
This publication was made possible in part by Grant Numbers DK071662, DK066202, and HL089301 from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung and Blood Institute, respectively. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Heart Lung and Blood Institute.
This work was supported by a Prostate Cancer Research Program Idea Development Award from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) of the U.S. Army Medical Research and Materiel Command.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Van Andel Research Institute.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- X. E. Zhou, K. M. Suino-Powell, J. Li, Y. He, J. P. MacKeigan, K. Melcher, E.-L. Yong, H. E. Xu. Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor. Journal of Biological Chemistry, 2010; 285 (12): 9161 DOI: 10.1074/jbc.M109.085779
Note: If no author is given, the source is cited instead.
more 
